

PICU Morbidity and Mortality Conference - 10/14/2022

Provided by

Speaker: Aravinth Prasanth Jawahar, MD

Topic: The Pediatric Critical Care morbidity and mortality conference (PICU M&M) is a monthly venue providing an interdisciplinary group of clinicians with an opportunity to discuss mortalities and their clinico-pathologic correlation in the PICU to advance continuing education. It also provides an opportunity to discuss medical error and adverse events focusing on systems issues and their solutions in an effort to promote patient safety at our institution. Participants include physicians, surgeons, nursing staff, respiratory therapists, pharmacists, pathologists, social workers, palliative care clinicians, care coordinators, safety specialists, hospital administrators, and other relevant consulting subspecialists.

Purpose or Objectives: At the conclusion of this activity, the participant will be able to:

- 1 Identify critically ill pediatric patients with unusual pathophysiology/diagnoses for which it would be appropriate to seek expert consultation and search the current literature to determine the best approach to diagnosis and management
- 2 Analyze contributing factors to patient adverse events using standard structural procedures.
- 3 Identify systems-based interventions to prevent future error based on isolated contributing factors.

Date/Time: 10/14/2022 1:00:00 PM

Location NICU Conf Rm (62220 SFCH)

Accreditation University of Iowa Roy J. and Lucille A. Carver College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this live activity for a maximum of **1.50 AMA PRA Category 1 Credit(s)™**. **Physicians should claim only the credit commensurate with the extent of their participation in the activity.**

Disclosure of Financial Relationships:

The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose:

Nothing to disclose - 03/30/2022